These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 15529137)

  • 1. Overdue process.
    Nat Biotechnol; 2004 Nov; 22(11):1329. PubMed ID: 15529137
    [No Abstract]   [Full Text] [Related]  

  • 2. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 3. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 4. Trials and error.
    Jacobs T
    Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
    [No Abstract]   [Full Text] [Related]  

  • 5. A critical tipping point.
    Zuckerman MB
    US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
    [No Abstract]   [Full Text] [Related]  

  • 6. The drive to reform the FDA gains momentum.
    Gatty B
    Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
    [No Abstract]   [Full Text] [Related]  

  • 7. Generic drug approval: a US perspective.
    Nagori BP; Mathur V; Garg S
    Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA embraces risk-management approach.
    Fox JL
    Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract]   [Full Text] [Related]  

  • 10. Getting SMART (submission management and review tracking) drug review in the computer age.
    Flieger K
    FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines.
    Heller WM
    Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792
    [No Abstract]   [Full Text] [Related]  

  • 12. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
    Lee VH
    Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
    [No Abstract]   [Full Text] [Related]  

  • 13. Putting pharmacogenetics into practice.
    Hopkins MM; Ibarreta D; Gaisser S; Enzing CM; Ryan J; Martin PA; Lewis G; Detmar S; van den Akker-van Marle ME; Hedgecoe AM; Nightingale P; Dreiling M; Hartig KJ; Vullings W; Forde T
    Nat Biotechnol; 2006 Apr; 24(4):403-10. PubMed ID: 16601719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study critiques corporate control of trials.
    Niiler E
    Nat Biotechnol; 2002 Dec; 20(12):1180. PubMed ID: 12454659
    [No Abstract]   [Full Text] [Related]  

  • 15. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 17. China offers alternative gateway for experimental drugs.
    Jia H; Kling J
    Nat Biotechnol; 2006 Feb; 24(2):117-8. PubMed ID: 16465139
    [No Abstract]   [Full Text] [Related]  

  • 18. McClellan's FDA: boon to industry, consumers, or both? New FDA chief plans to speed drug approval and reduce costs.
    Ault A
    Lancet; 2003 Aug; 362(9381):379-80. PubMed ID: 12911016
    [No Abstract]   [Full Text] [Related]  

  • 19. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 20. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
    Kesselheim AS
    Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.